Boehringer Ingelheim commits to Veeva Vault CRM
Systems announced that Boehringer Ingelheim is the latest global top 20 biopharma company to commit to moving to Veeva Vault CRM.
pharmaphorum4d
Boehringer’s survodutide shows monster MASH potential
Boehringer Ingelheim’s weight-loss drug candidate survodutide could also be effective for liver disease metabolic dysfunction-associated steatohepatitis (MASH), if the results of a mid-stage ...
pharmaphorum2d
Seeking Ofev successor, Boehringer takes PDE4B drug into phase 3
Boehringer Ingelheim has moved one of its top pipeline prospects – oral phosphodiesterase 4B (PDE4B) inhibitor BI 1015550 – into late-stage clinical testing for idiopathic pulmonary fibrosis ...
Altimmune says pemvidutide given ‘clean safety bill of health’ by FDA
At the Guggenheim Securities Healthcare Innovation Conference, Altimunne said earlier: “So the first thing is that survodutide has a ...
Future Market Insights5d
Middle East Veterinary Vaccine Market to Reach USD 973.8 Million by 2033, Growing at a 4% CAGR
The Middle East Veterinary Vaccine Market is poised for steady growth, with a projected market size of USD 627.1 million in 2023. The market is expected to expand at a CAGR of 4% through 2033, ...